Share Search
Visit the Share Search
AstraZeneca's Brilinta approved in the US to reduce risk of stroke
6th Nov 2020 08:07
(Sharecast News) - AstraZeneca said on Friday that its Brilinta drug has been approved in the US to reduce the risk of stroke.
The approval by the US Food and Drug Administration, for use in patients with acute ischemic stroke or high-risk transient ischaemic attack (TIA), was based on positive results from the THALES Phase III trial. It showed that aspirin plus Brilinta 90mg significantly reduced the rate of the composite of stroke and death compared to aspirin alone.
An ischaemic stroke is caused by a blockage cutting off the blood supply to a region of the brain. A transient ischaemic attack is a temporary blockage of the blood supply to a region of the brain, resulting in symptoms only lasting for a short amount of time.
Mene Pangalos, executive vice president of BioPharmaceuticals R&D, said: "In the US, someone has a stroke every 40 seconds and the impact on a person's life can be truly devastating.
"Brilinta is a well-established medicine across patients with coronary artery disease and with today's approval, we can now expand its potential to patients with an acute ischaemic stroke or transient ischemic attack."
The approval by the US Food and Drug Administration, for use in patients with acute ischemic stroke or high-risk transient ischaemic attack (TIA), was based on positive results from the THALES Phase III trial. It showed that aspirin plus Brilinta 90mg significantly reduced the rate of the composite of stroke and death compared to aspirin alone.
An ischaemic stroke is caused by a blockage cutting off the blood supply to a region of the brain. A transient ischaemic attack is a temporary blockage of the blood supply to a region of the brain, resulting in symptoms only lasting for a short amount of time.
Mene Pangalos, executive vice president of BioPharmaceuticals R&D, said: "In the US, someone has a stroke every 40 seconds and the impact on a person's life can be truly devastating.
"Brilinta is a well-established medicine across patients with coronary artery disease and with today's approval, we can now expand its potential to patients with an acute ischaemic stroke or transient ischemic attack."